Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25995253 | 1.00 | ALOX15 (0.39) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995227 | 1.00 | ALOX15 (0.39) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995226 | 1.00 | ALOX15 (0.39) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995239 | 1.00 | ALOX15 (0.39) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995265 | 1.00 | ALOX15 (0.39) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995194 | 0.98 | ALOX15 (0.40) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25995161 | 0.93 | ALOX15 (0.41) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25998525 | 0.91 | PTGS2 (0.35) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25998282 | 0.91 | PTGS2 (0.35) | ALOX15CYP2C9HSD17B10PTGS2NPC1 | |
| SCHEMBL25998277 | 0.91 | PTGS2 (0.35) | ALOX15CYP2C9HSD17B10PTGS2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | ALOX15 307/4885CYP2C9 460/4885HSD17B10 279/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | ALOX15 325/4885CYP2C9 750/4885HSD17B10 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.